Lupin Peer Comparison

NSE: LUPIN | BSE: 500257

₹2,092.00

₹-8.70 (-0.41%)

As on 25-Sep-2026IST

Market cap

₹95,574 Cr

Revenue (TTM)

₹29,967 Cr

P/E Ratio

17.3

P/B Ratio

Div. Yield

0.9 %

Edit

	Lupin	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Market cap (₹ Cr)	95,574	1,19,900	1,02,247	1,00,395	98,464
Revenue (₹ Cr)	29,967	28,592	14,738	33,228	34,935
Net Profit (₹ Cr)	5,551.01	4,492.20	2,055.11	3,169.30	3,712.74
Net Margin (%)	18.23	14.92	13.64	9.15	10.42
RoE (%)	28.32	18.78	13.60	8.72	10.38
Price to Earnings	17.29	26.57	50.06	31.16	26.52
Price-To-Book	4.02	4.45	6.08	2.63	2.53

Income Statement (₹ Cr)

	Lupin	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Operating Revenue	29,966.58	28,591.70	14,737.88	33,227.90	34,935.29
Total Income	30,442.31	30,111.40	15,061.79	34,650.70	35,624.79
Total Expenditure	20,428.27	21,334.70	10,911.05	28,088.10	27,850.01
EBITDA	9,538.31	7,257.00	3,826.83	5,139.80	7,085.28
Depreciation	1,529.37	1,724.60	893.20	2,119.30	1,859.31
EBIT	8,008.94	5,532.40	2,933.63	3,020.50	5,225.97
Interest	452.37	510.20	578.61	416.30	387.88
Other Income	475.73	1,519.70	323.91	1,422.80	689.50
Exceptional Items	-557.91	-534.80	-129.75	0.00	-105.51
Profit before Tax	7,474.39	6,007.10	2,549.18	4,027.00	5,422.08
Provision for Tax	1,923.38	1,514.90	494.07	857.70	1,709.34
Profit after Tax	5,551.01	4,492.20	2,055.11	3,169.30	3,712.74

	Lupin	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Shareholder's Funds	22,448.27	27,111.40	16,300.34	37,891.50	37,890.97
Minority Interest	-22.18	-79.70	-24.90	38.90	1.76
Non-Current Liabilities	3,200.22	7,112.50	5,011.23	3,145.10	2,580.33
Current Liabilities	12,651.24	15,711.90	6,507.25	16,747.40	18,039.01
Total Liabilities	38,146.06	50,672.60	27,754.83	56,576.70	58,196.15

	Lupin	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Non-Current Assets	11,888.82	31,677.20	20,274.65	27,204.00	24,040.45
Current Assets	24,027.38	19,906.10	6,954.20	30,179.30	32,708.75
Total Assets	38,146.06	50,672.60	27,754.83	56,576.70	58,196.15
Total Debt*	5,910.20	11,769.50	6,021.78	7,734.10	7,676.20
Net Current Assets	11,376.14	4,194.20	446.95	13,431.90	14,669.74
Contingent Liabilities	1,094.02	989.90	924.77	336.14	1,358.37

	Lupin	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Cash From Operating Activities	7,334.50	2,116.60	3,121.29	5,673.70	5,526.37
Cash Flow from Investing Activities	-3,864.59	-8,296.10	-196.42	-6,549.30	-3,458.61
Cash from Financing Activities	-845.87	5,806.90	-2,952.69	829.00	-1,269.15
Net Cash Inflow / Outflow	2,624.04	-372.60	-27.82	-46.60	798.61

	Lupin	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
ROCE (%)	28.86	21.39	13.24	13.75	12.76
ROE (%)	28.32	18.78	13.60	8.72	10.38
ROA (%)	16.43	10.03	7.36	5.89	6.86
EBIT Margin (%)	26.73	19.35	19.91	9.09	14.96
Net Margin (%)	18.23	14.92	13.64	9.15	10.42
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Lupin	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Revenue Growth (%)	28.19	21.11	14.16	-0.87	9.09
EBIT Growth (%)	77.03	-8.99	19.45	-55.06	6.91
Net Profit Growth (%)	49.13	-3.14	8.09	-44.66	8.63
EPS Growth (%)	60.86	4.31	12.27	-43.29	11.88
Book Value Growth (%)	30.75	13.19	13.74	12.99	16.04

	Lupin	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Price / Earnings	16.03	24.53	47.57	31.16	26.19
Price / Book Value	4.02	4.45	6.08	2.63	2.53
Dividend Yield (%)	0.86	0.08	0.04	0.67	0.23
EV/EBITDA	9.67	17.15	27.76	19.67	13.48
Market Cap (₹ Cr)	1,05,737.27	87,643.18	82,801.75	1,04,763.81	75,689.14

	Lupin	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Debt to Equity	0.07	0.12	0.17	0.00	0.02
Short term debt to equity ratio	0.18	0.16	0.04	0.16	0.16
Current Ratio	1.90	1.27	1.07	1.80	1.81
Quick Ratio	1.42	0.91	0.74	1.35	1.15
Interest Coverage	17.52	12.77	5.41	10.67	14.98

	Lupin	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Debtors to sales (%)	22.04	18.94	11.74	30.47	20.31
Asset Turnover	0.89	0.64	0.53	0.62	0.65
Receivable days	51.23	33.55	39.93	103.79	33.71
Inventory Days	48.93	33.80	51.78	79.94	59.32
Payable days	205.75	149.82	111.46	84.78	148.20
Cash Conversion Cycle	-105.59	-82.46	-19.75	98.95	-55.17

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.